APA (7th ed.) Citation

AlRuthia, Y., Alfakhri, A. H., Alharbi, I., Alghamdi, F. A., Alanazi, M. A., Alrabiah, A. A., . . . Almasaoud, M. A. (2023). Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: A real-world study in Saudi Arabia. Cost Effectiveness & Resource Allocation, 21(1), 1. https://doi.org/10.1186/s12962-023-00504-1

Chicago Style (17th ed.) Citation

AlRuthia, Yazed, Almaha H. Alfakhri, Ibtisam Alharbi, Fadi Ali Alghamdi, Miteb A. Alanazi, Abdullah Abdulrahman Alrabiah, Anwar Abdulrazzag Alsouan, Abdulrahman Abdullah Alshaikh, and Majed Ali Almasaoud. "Comparative Effectiveness and Cost Evaluation of Risankizumab and Adalimumab in the Management of Psoriasis: A Real-world Study in Saudi Arabia." Cost Effectiveness & Resource Allocation 21, no. 1 (2023): 1. https://doi.org/10.1186/s12962-023-00504-1.

MLA (9th ed.) Citation

AlRuthia, Yazed, et al. "Comparative Effectiveness and Cost Evaluation of Risankizumab and Adalimumab in the Management of Psoriasis: A Real-world Study in Saudi Arabia." Cost Effectiveness & Resource Allocation, vol. 21, no. 1, 2023, p. 1, https://doi.org/10.1186/s12962-023-00504-1.